Roth Capital Has Bearish Forecast for BRTX FY2029 Earnings

BioRestorative Therapies, Inc. (NASDAQ:BRTX) – Research analysts at Roth Capital cut their FY2029 EPS estimates for BioRestorative Therapies in a note issued to investors on Friday, March 28th. Roth Capital analyst J. Aschoff now forecasts that the company will post earnings of $6.86 per share for the year, down from their prior forecast of $6.93. The consensus estimate for BioRestorative Therapies’ current full-year earnings is ($1.43) per share.

BioRestorative Therapies Stock Down 1.7 %

BRTX stock opened at $1.78 on Monday. The stock has a market capitalization of $12.32 million, a price-to-earnings ratio of -1.16 and a beta of 64.37. BioRestorative Therapies has a 52-week low of $1.03 and a 52-week high of $2.55. The stock’s fifty day simple moving average is $1.97 and its 200-day simple moving average is $1.73.

BioRestorative Therapies (NASDAQ:BRTX) last released its earnings results on Thursday, March 27th. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.07. The firm had revenue of $0.50 million during the quarter, compared to analysts’ expectations of $0.48 million. BioRestorative Therapies had a negative net margin of 2,697.08% and a negative return on equity of 98.49%.

Institutional Trading of BioRestorative Therapies

An institutional investor recently bought a new position in BioRestorative Therapies stock. Citadel Advisors LLC acquired a new stake in shares of BioRestorative Therapies, Inc. (NASDAQ:BRTX) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 21,481 shares of the company’s stock, valued at approximately $31,000. Citadel Advisors LLC owned about 0.31% of BioRestorative Therapies at the end of the most recent reporting period. 69.38% of the stock is owned by institutional investors.

BioRestorative Therapies Company Profile

BioRestorative Therapies, Inc, a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders.